![]() A recent article in Fierce Healthcare covered the Partnership for Part D Access’s new report showing Medicare Part D plans are successfully using tools to drive patients into less expensive drugs. The article, which highlights the Partnership’s response to the Trump administration’s new drug pricing proposal, points out that anti-rejection drugs for patients who've received transplants, antiretrovirals for patients with HIV, and anticonvulsants for patients with epilepsy among a few of the many therapies that could get more restricted under this proposed rule. "While on its face, the proposal the administration has put out seems to make tweaks, we as a patient community have concerns that [it] would dramatically impact access," said Partnership Senior Advisor Catherine Finley.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
September 2023
Categories |
Learn more |
What's New? |
|